About Cylex: Investors

Cylex is a venture-backed, privately held global life sciences company whose investors are leaders in life science investing. In addition to the expertise of the Cylex Board of Directors, each investor brings considerable strategic, financial and scientific expertise to the Company.

Canaan Partners invests in visionary entrepreneurs and provides them the networks, insights and operational guidance required to build high-performance technology and healthcare companies. Founded in 1987, the firm has raised eight funds and completed more than 78 acquisitions and 53 IPOs. With $3 billion under management and a worldwide footprint, the firm is committed to catalyzing the growth of innovative digital media, communications & mobility, enterprise, clean tech, biopharmaceutical, medical device, diagnostics and healthcare infrastructure companies. Among its successes are Amicus Therapeutics, a pioneer of next-generation oral therapies for the management of human genetic diseases; BiPar Sciences, a biopharmaceutical company pioneering novel tumor-selective therapies to address urgent unmet needs of cancer patients; Calixa Therapeutics, developer of hospital-based antibiotics to treat infections resulting from resistant strains of bacteria; and Cerexa Inc., one of the largest biotech acquisitions of 2007. Other Canaan investments include Advanced BioHealing, Calibra Medical, Chimerix, Inc., CoAxia, Liquidia Technologies, ReVision Optics, Theraclone Sciences, Transcend Medical, and VaxInnate.  Canaan has offices in California, Connecticut, India and Israel.

http://www.canaan.com

Channel Medical Partners invests solely in public emerging growth companies in the medical technology industries. In this market segment, the Fund not only acts as a significant source of capital, it also adds substantial value by helping portfolio compnies put into place the capabilities required for success. Over the past few years, they have led some of the larger transactions completed in the medical technology industry.

http://www.chanmed.com

First Analysis is a leading private growth equity investor. They have one of the longest records (23 years) in private capital investing, transitioning through three major long-term investment cycles. They have invested over $650 million across multiple highly diversified funds and created over $1.5 billion in fund liquidations. The Company has over $260 million in active portfolio investments.  They apply a unique strategy - achieving broad, deep, and long-term domain expertise through a research and investment focus that encompasses both private and public companies. This approach yields valuable perspective and service.

http://www.firstanalysis.com

Roche Venture Fund which invests in early stage biotech and diagnostics companies to support innovative technologies and medicines. Based in Basel, Switzerland, the Roche Venture Fund, with a portfolio of over 25 companies in 10 countries, is constantly seeking new investment opportunities in innovative companies with novel technologies.

http://www.venturefund.roche.com

http://www.siemens.com/venturecapital